{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:19:31Z","timestamp":1793420371296,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jacadv.2024.101511","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T18:10:30Z","timestamp":1734631830000},"page":"101511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of Tafamidis on Clinical and Functional Parameters in Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1016","volume":"4","author":[{"given":"Ting-Wei","family":"Kao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsin","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5512-9395","authenticated-orcid":false,"given":"An-Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Feng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Yuan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chao","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2859-5117","authenticated-orcid":false,"given":"Cheng-Hsuan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8153-1441","authenticated-orcid":false,"given":"Yen-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2024.101511_bib1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A\u00a0European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2024.101511_bib2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jcmg.2022.07.008","article-title":"Multi-imaging characterization of cardiac phenotype in different types of amyloidosis","volume":"16","author":"Ioannou","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacadv.2024.101511_bib3","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.101511_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters","volume":"10","author":"Pagourelias","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacadv.2024.101511_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s10741-019-09796-z","article-title":"Speckle tracking echocardiography in cardiac amyloidosis","volume":"24","author":"Stricagnoli","year":"2019","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacadv.2024.101511_bib6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","article-title":"Cardiovascular magnetic resonance in cardiac amyloidosis","volume":"111","author":"Maceira","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2024.101511_bib7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ehf2.13693","article-title":"99m Technetium-pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy","volume":"9","author":"Tahara","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacadv.2024.101511_bib8","first-page":"544","article-title":"The hidden heart disease: shedding light on cardiac amyloidosis","volume":"39","author":"Tsai","year":"2023","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.jacadv.2024.101511_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacadv.2024.101511_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12968-020-00689-x","article-title":"Is a timely assessment of the hematocrit necessary for cardiovascular magnetic resonance-derived extracellular volume measurements?","volume":"22","author":"Su","year":"2020","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"issue":"8 Suppl","key":"10.1016\/j.jacadv.2024.101511_bib11","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.cardfail.2011.06.190","article-title":"Tafamidis stabilizes transthyretin and improves clinical outcomes in transthyretin amyloid cardiomyopathy","volume":"17","author":"Falk","year":"2011","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacadv.2024.101511_bib12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","article-title":"Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis","volume":"6","author":"Merlini","year":"2013","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.jacadv.2024.101511_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2024.101511_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacadv.2024.101511_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.amjcard.2021.02.035","article-title":"Causes of cardiovascular hospitalization and death in patients with transthyretin amyloid cardiomyopathy (from the tafamidis in transthyretin cardiomyopathy clinical trial [ATTR-ACT])","volume":"148","author":"Miller","year":"2021","journal-title":"Am J Cardiol"},{"issue":"Issue Supplement_1","key":"10.1016\/j.jacadv.2024.101511_bib16","article-title":"Cardiac imaging in tafamidis-treatment patients with transthyretin amyloid cardiomyopathy","volume":"42","author":"Rettl","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2024.101511_bib17","first-page":"216","article-title":"A\u00a0novel quantitative method for assessing the therapeutic response to Tafamidis therapy in patients with cardiac TTR amyloidosis. A preliminary report","volume":"25","author":"Doumas","year":"2022","journal-title":"Hell J Nucl Med"},{"key":"10.1016\/j.jacadv.2024.101511_bib18","article-title":"The use of SPECT\/CT quantification of 99mTc-PYP uptake to assess tafamidis treatment response in ATTR cardiac amyloidosis","volume":"22","author":"Elsadany","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacadv.2024.101511_bib19","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis","volume":"23","author":"Giblin","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacadv.2024.101511_bib20","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1253\/circj.CJ-21-0965","article-title":"Early experience of tafamidis treatment in Japanese patients with wild-type transthyretin cardiac amyloidosis from the Kochi amyloidosis cohort","volume":"86","author":"Ochi","year":"2022","journal-title":"Circ J"},{"key":"10.1016\/j.jacadv.2024.101511_bib21","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.jcmg.2022.06.013","article-title":"Tafamidis decreases cardiac uptake of 99mTc-HMDP in transthyretin cardiac amyloidosis","volume":"15","author":"Odouard","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacadv.2024.101511_bib22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","article-title":"Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy","volume":"23","author":"Rettl","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacadv.2024.101511_bib23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00392-022-02035-w","article-title":"Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging","volume":"112","author":"Chamling","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacadv.2024.101511_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.101511_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101667","article-title":"Real-world efficacy of tafamidis in patients with transthyretin amyloidosis and heart failure","volume":"48","author":"Ghoneem","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.jacadv.2024.101511_bib26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1253\/circj.CJ-22-0683","article-title":"Impact of tafamidis on echocardiographic cardiac function of patients with transthyretin cardiac amyloidosis","volume":"87","author":"Ichikawa","year":"2023","journal-title":"Circ J"},{"key":"10.1016\/j.jacadv.2024.101511_bib27","article-title":"Comparative outcomes of a transthyretin amyloid cardiomyopathy cohort versus patients with heart failure with preserved ejection fraction enrolled in the TOPCAT trial","volume":"12","author":"Kim","year":"2023","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2024.101511_bib28","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s11604-023-01403-4","article-title":"Follow-up Tc-99 m pyrophosphate cardiac scan for patients with transthyretin cardiac amyloidosis treated with tafamidis","volume":"41","author":"Lee","year":"2023","journal-title":"Jpn J Radiol"},{"key":"10.1016\/j.jacadv.2024.101511_bib29","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.101511_bib30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1536\/ihj.23-075","article-title":"Changes in exercise tolerance over time in patients with transthyretin amyloidosis cardiomyopathy treated with tafamidis","volume":"64","author":"Nakaya","year":"2023","journal-title":"Int Heart J"},{"key":"10.1016\/j.jacadv.2024.101511_bib31","article-title":"Regression of myocardial 99mTc-DPD uptake after tafamidis treatment of cardiac transthyretin amyloidosis","volume":"122","author":"Papathanasiou","year":"2023","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jacadv.2024.101511_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/jead030","article-title":"Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy","author":"Rettl","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacadv.2024.101511_bib33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ejhf.2783","article-title":"Effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis: insights from pressure-volume analysis of the APOLLO study","volume":"25","author":"Rosenblum","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2024.101511_bib34","article-title":"Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR-ACT randomized clinical trial","author":"Shah","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2024.101511_bib35","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/ehf2.14380","article-title":"Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy","volume":"10","author":"Takashio","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacadv.2024.101511_bib36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13023-023-02824-0","article-title":"Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study","volume":"18","author":"Tsai","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jacadv.2024.101511_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/20406223231222828","article-title":"Tafamidis improves myocardial longitudinal strain in A97S transthyretin cardiac amyloidosis","volume":"15","author":"Wu","year":"2024","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.jacadv.2024.101511_bib38","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jcmg.2022.12.016","article-title":"Tafamidis treatment decreases 99mTc-Pyrophosphate uptake in patients with hereditary Ala97Ser transthyretin amyloid cardiomyopathy","volume":"16","author":"Yu","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacadv.2024.101511_bib39","first-page":"284","article-title":"Multiparametric monitoring of disease progression in contemporary patients with wild-type transthyretin amyloid cardiomyopathy initiating tafamidis treatment","volume":"13","author":"Ney","year":"2024","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jacadv.2024.101511_bib40","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jacadv.2024.101511_bib41","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/ejhf.2589","article-title":"Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis","volume":"24","author":"Antonopoulos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2024.101511_bib42","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2024.101511_bib43","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/ehjci\/jew325","article-title":"Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid","volume":"18","author":"Hutt","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacadv.2024.101511_bib44","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacadv.2024.101511_bib45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1532-429X-15-92","article-title":"Myocardial T1 mapping and extracellular volume quantification: a society for cardiovascular magnetic resonance (SCMR) and CMR working group of the European society of cardiology consensus statement","volume":"15","author":"Moon","year":"2013","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jacadv.2024.101511_bib46","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2024.101511_bib47","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/ehjci\/jev227","article-title":"Direct comparison of cardiac magnetic resonance feature tracking and 2D\/3D echocardiography speckle tracking for evaluation of global left ventricular strain","volume":"17","author":"Obokata","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacadv.2024.101511_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102172","article-title":"Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis","volume":"63","author":"Wang","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X24007919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X24007919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T03:15:54Z","timestamp":1768965354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X24007919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2772963X24007919"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2024.101511","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Tafamidis on Clinical and Functional Parameters in Transthyretin Amyloid Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2024.101511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101511"}}